These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 17373899)
21. Introducing human papillomavirus vaccines - questions remain. Paavonen J; Lehtinen M Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882 [TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus typing and the reduction of cervical cancer risk. Jin XW; Cash J; Kennedy AW Cleve Clin J Med; 1999 Oct; 66(9):533-9. PubMed ID: 10535179 [TBL] [Abstract][Full Text] [Related]
23. Variation in genital human papillomavirus infection prevalence and vaccination coverage among men and women in the USA. Han JJ; Tarney CM; Song J Future Oncol; 2017 Jun; 13(13):1129-1132. PubMed ID: 28589730 [TBL] [Abstract][Full Text] [Related]
24. Current acceptance of the HPV vaccine. Miller MM; Wilson JM; Waldrop J Nurse Pract; 2008 Apr; 33(4):18-22; quiz 22-3. PubMed ID: 18388548 [No Abstract] [Full Text] [Related]
25. Journey of the Human Papillomavirus (HPV) in a Developing Country over 5 Years (2010 - 2015). Danial M; Sivasangari S; Arulappen A; Ong L Asian Pac J Cancer Prev; 2016; 17(3):1363-8. PubMed ID: 27039773 [TBL] [Abstract][Full Text] [Related]
26. Current clinical trials of HPV vaccines. Trimble EL; Schoenfeldt M Oncology (Williston Park); 2004 Jun; 18(7):859-60, 862. PubMed ID: 15255170 [No Abstract] [Full Text] [Related]
27. Human papillomavirus vaccines and prevention of cervical cancer. Jansen KU; Shaw AR Annu Rev Med; 2004; 55():319-31. PubMed ID: 14746524 [TBL] [Abstract][Full Text] [Related]
28. U.S. girls to receive HPV vaccine but picture unclear on potential worldwide use, acceptance. Twombly R J Natl Cancer Inst; 2006 Aug; 98(15):1030-2. PubMed ID: 16882936 [No Abstract] [Full Text] [Related]
29. [Advances in Understanding Carcinogenetic Mechanisms of the Human Papillomavirus and Vaccines Based on Virus-like Particles]. Zhao Z; Wang L; Ma B Bing Du Xue Bao; 2015 Mar; 31(2):180-6. PubMed ID: 26164945 [TBL] [Abstract][Full Text] [Related]
30. [BENEFITS AND RISKS AT IMPLEMENTATION OF PROPHILACTIC VACCINES FOR CERVICAL CANCER]. Zlatkov V; Kostova P Akush Ginekol (Sofiia); 2016; 55(3):28-33. PubMed ID: 27514142 [TBL] [Abstract][Full Text] [Related]
32. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. Mendez F; Munoz N; Posso H; Molano M; Moreno V; van den Brule AJ; Ronderos M; Meijer C; Munoz A; J Infect Dis; 2005 Oct; 192(7):1158-65. PubMed ID: 16136457 [TBL] [Abstract][Full Text] [Related]
33. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067 [TBL] [Abstract][Full Text] [Related]
34. Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention. Garcia FA; Saslow D Obstet Gynecol Clin North Am; 2007 Dec; 34(4):761-81, ix. PubMed ID: 18061868 [TBL] [Abstract][Full Text] [Related]
35. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France. Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I; J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911 [TBL] [Abstract][Full Text] [Related]